The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...

The upfront cash payment of $4.10 per share of common stock represents a premium of around 66% to Checkpoint’s closing share ...

Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

Sun Pharma to acquire Checkpoint Therapeutics, expanding innovative portfolio in onco-derm therapy with FDA-approved UNLOXCYT ...

A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...